SCHEMBL24334348

SCHEMBL24334348

Cc1ccc2cccc(S(=O)(=O)NC(=O)c3cc4c(F)cc(N5CCC5C)cc4o3)c2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.39
TSHR P16473 3/20 0.39
USP2 O75604 2/20 0.39
LMNA P02545 2/20 0.39
HSD17B10 Q99714 2/20 0.37
SMN1; SMN2 Q16637 5/20 0.37
TP53 P04637 4/20 0.37
KDM4E B2RXH2 1/20 0.37
LDHA P00338 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MAPK1 P28482 2/20 0.33
NFKBIA P25963 1/20 0.33
RELA Q04206 1/20 0.33
SLC40A1 Q9NP59 1/20 0.33
CRHBP P24387 1/20 0.32
CRHR2 Q13324 1/20 0.32
ABCB1 P08183 1/20 0.32
ABCC1 P33527 1/20 0.32
ABCG2 Q9UNQ0 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29469614 1.00 POLB (0.39) POLBTSHRUSP2LMNAHSD17B10
SCHEMBL24333785 0.91 POLB (0.38) POLBTSHRUSP2LMNAHSD17B10
SCHEMBL29469712 0.91 POLB (0.38) POLBTSHRUSP2LMNAHSD17B10
SCHEMBL29469722 0.90 POLB (0.37) POLBTSHRUSP2LMNAHSD17B10
SCHEMBL24334451 0.90 POLB (0.37) POLBTSHRUSP2LMNAHSD17B10
SCHEMBL24334001 0.87 POLB (0.42) POLBTSHRUSP2LMNAHSD17B10
SCHEMBL29469820 0.87 POLB (0.42) POLBTSHRUSP2LMNAHSD17B10
SCHEMBL24333584 0.86 POLB (0.40) POLBTSHRUSP2LMNAHSD17B10
SCHEMBL29469615 0.86 POLB (0.40) POLBTSHRUSP2LMNAHSD17B10
SCHEMBL24334337 0.84 POLB (0.39) POLBTSHRUSP2LMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022081807-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. (US) 2022-04-21 WO disclosed